In this review:
- TRUST: radical upfront surgical therapy in advanced ovarian cancer
- KEYNOTE-A18: final analysis
- ROSELLA: relacorilant plus nab-paclitaxel in platinum resistant ovarian cancer
- OUTBACK: patient-reported outcomes in locally advanced cervical cancer
- COMPASSION-16: subgroup analyses of cadonilimab plus chemotherapy with/without bevacizumab
- Cytoreductive surgery with/ without HIPEC in advanced/ recurrent ovarian cancer
- FIRST: first-line dostarlimab plus niraparib in advanced ovarian cancer
- Induction chemotherapy plus chemoradiotherapy for locally advanced cervical cancer
- PFS as a surrogate outcome for OS in RCTs of maintenance therapies in ovarian cancer
Please login below to download this issue (PDF)